glp-1 drugs tirzepatide Associated with Lower POAG, OHT Risk Compared with Other Compounded GLP-1 - Semaglutide &

The trials also revealed non-inferior efficacy and a safety profile with that of the reference liraglutide

Sikirica, M

Despite the current lack of impact, the company expects changes in consumer behavior, including reduced calorie intake and less snacking, due to the rapid adoption of these medications

I think the stuff is great, one physician responded

doi: 10.1186/s12889-023-16194-6.10.1186/s12889-023-16194-6 [DOI] [PMC free article] [PubMed] [Google Scholar] 41.Holmes WS, Moorhead SA, Coates VE, Bond RR, Zheng H

Specific to cardiovascular-related death, ELIXA and SUSTAIN-6 trials showed similar performance relative to the placebo [ HR = 0.98 (95% CI 0.781.22) and HR = 0.98 (95% CI 0.651.48), respectively]